Updated:
BioLineRx Ltd.
BioLineRx Ltd. is an Israeli biopharma firm led by Philip Serlin, advancing oncology assets like Motixafortide through public markets and partnerships.
BioLineRx Ltd.
BioLineRx Ltd. was founded in 2003 in Israel as a biopharmaceutical development company. Its lead asset, Motixafortide, completed a successful Phase 3 trial (GENESIS) in 2023 for stem-cell mobilization in multiple myeloma patients. The company is publicly traded on NASDAQ (BLRX) and the Tel Aviv Stock Exchange, giving it a capital-markets component unusual for a typical development-stage biotech. The firm concentrates its pipeline on oncology and immuno-oncology, with Motixafortide as the primary candidate. Additional early-stage programs target pancreatic cancer and other solid tumors. BioLineRx employs a dual strategy: advancing internal drug candidates while also licensing or co-developing assets with larger pharmaceutical partners. In 2023, the company entered a clinical collaboration with Novartis to evaluate Motixafortide in combination with other therapies (per company press release, 2023). As of 2024, BioLineRx had approximately 20 employees, with its headquarters in Modi'in, Israel, and a U.S. commercial presence established in 2023. The company raised capital through public offerings and a $20 million debt facility with Kreos Capital in 2023. It operates no adjacent investment vehicles or philanthropic arms outside its core R&D mission. BioLineRx's structural differentiator is its publicly traded status: it functions as a development-stage biotech subject to SEC reporting, not a privately held family office. The firm's governance includes an independent board and institutional shareholders. Its financing model relies on equity offerings and debt, not wealthy-principal capital — a key signal for allocators evaluating its risk profile.
General information
Firm type
other
Year founded
2003
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Modi'in
Corporate office
Modi'in, Israel
Principals
Philip Serlin
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at BioLineRx?
Philip Serlin serves as Chief Executive Officer and oversees corporate strategy. The firm's board of directors, which includes representatives from institutional investors, approves major capital allocation decisions.
Is BioLineRx structured as a family office or a public biotech?
BioLineRx is a publicly traded biopharmaceutical company on NASDAQ and the Tel Aviv Stock Exchange, not a family office. It operates with a traditional corporate governance structure and disclosure obligations under SEC rules.
What investment stages does BioLineRx typically target?
BioLineRx focuses on clinical-stage drug development, primarily Phase 2 and Phase 3 trials. It does not invest in other companies; its capital is deployed into internal R&D and licensing agreements.
Which sectors does BioLineRx explicitly avoid?
BioLineRx concentrates exclusively on oncology and immuno-oncology. It does not participate in other therapeutic areas such as cardiovascular, neurology, or rare diseases.
How is BioLineRx related to Novartis?
BioLineRx entered a clinical collaboration with Novartis in 2023 to evaluate Motixafortide in combination with other therapies (per company press release, 2023). This is a non-equity partnership.
Where does the underlying wealth come from?
BioLineRx is a publicly traded company with diverse institutional and retail shareholders. No single family or individual controls a majority stake, and its funding comes from equity offerings and debt facilities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: